What's Behind Myriad Genetics' Disastrous Q1 Performance
It's been feast or famine for Myriad Genetics (NASDAQ: MYGN) this year. The stock has skyrocketed more than 50% in a single day. And it has dropped by nearly that much in one day as well.
The genetic testing company announced its fiscal 2020 first-quarter results after the market closed on Monday. And it looks like there will be another famine. Here are the highlights from Myriad's first-quarter update.
Image source: Getty Images.
Source Fool.com
